Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet 2016; 387:1094-108. doi: 10.1016/S0140-6736(15)00130-0MoricePLearyACreutzbergCAbu-RustumNDaraiEEndometrial cancer2016387109410810.1016/S0140-6736(15)00130-0Open DOISearch in Google Scholar
Repše-Fokter A. Endometrial cancer in young woman. Acta Medico– Biotechnica 2020; 13: 60-4.Repše-FokterA.Endometrial cancer in young woman202013604Search in Google Scholar
Zadnik V, Zagar T, Lokar K, Tomsic S, Konjevic AD, Zakotnik B. Trends in population-based cancer survival in Slovenia. Radiol Oncol 2021; 55: 42-9. doi: 10.2478/raon-2021-0003ZadnikVZagarTLokarKTomsicSKonjevicADZakotnikBTrends in population-based cancer survival in Slovenia20215542910.2478/raon-2021-0003787726133885247Open DOISearch in Google Scholar
Concin N, Matias-guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31: 12-39. doi: 10.1136/ijgc-2020-002230ConcinNMatias-guiuXVergoteICibulaDMirzaMRMarnitzSet alESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma202131123910.1136/ijgc-2020-00223033397713Open DOISearch in Google Scholar
Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer 2019; 19: 510-21. doi: 10.1038/s41568-019-0177-xUrickMEBellDWClinical actionability of molecular targets in endometrial cancer2019195102110.1038/s41568-019-0177-x744624331388127Open DOISearch in Google Scholar
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73. doi: 10.1038/nature12113CancerGenome Atlas Research NetworkKandothCSchultzNet alIntegrated genomic characterization of endometrial carcinoma2013497677310.1038/nature12113370473023636398Open DOISearch in Google Scholar
Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 2018; 119: 1067-74. doi: 10.1038/s41416-018-0310-8WortmanBGCreutzbergCLPutterHJürgenliemk-SchulzIMJobsenJJLutgensLCHWet alTen-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy201811910677410.1038/s41416-018-0310-8621949530356126Open DOISearch in Google Scholar
McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, et al. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. Cancer 2021; 26: 5400-10. doi: 10.1002/cncr.33516McAlpineJNChiuDSNoutRAChurchDNSchmidtPLamSet alEvaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis20212654001010.1002/cncr.3351633793971Open DOISearch in Google Scholar
Vermij L, Smit V, Nout R, Bosse T. Incorporation of molecular characteristics into endometrial cancer management. Histopathology 2020; 76: 52-63. doi: 10.1111/his.14015VermijLSmitVNoutRBosseTIncorporation of molecular characteristics into endometrial cancer management202076526310.1111/his.14015697255831846532Open DOISearch in Google Scholar
Abdulfatah E, Wakeling E, Sakr S, Al-Obaidy K, Bandyopadhyay S, Morris R, et al. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management. Gynecol Oncol 2019; 154: 467-74. doi: 10.1016/j.ygyno.2019.06.012AbdulfatahEWakelingESakrSAl-ObaidyKBandyopadhyaySMorrisRet alMolecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management20191544677410.1016/j.ygyno.2019.06.01231248668Open DOISearch in Google Scholar
Malentacchi F, Turrini I, Sorbi F, Projetto E, Castiglione F, Vergoni F, et al. Identification of a gene panel for endometrioid endometrial cancer: a possible prognostic value? Reprod Sci 2020; 27: 592-8. doi: 10.1007/s43032-019-00059-8MalentacchiFTurriniISorbiFProjettoECastiglioneFVergoniFet alIdentification of a gene panel for endometrioid endometrial cancer: a possible prognostic value?202027592810.1007/s43032-019-00059-832046431Open DOISearch in Google Scholar
McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538-49. doi: 10.1002/path.5034McAlpineJLeon-CastilloABosseTThe rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses20182445384910.1002/path.503429344951Open DOISearch in Google Scholar
Raffone A, Travaglino A, Cerbone M, Guida M, Insabato L, Zannoni GF, et al. Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer. Pathol Oncol Res 2020; 26: 1417-27. doi: 10.1007/s12253-020-00811-5RaffoneATravaglinoACerboneMGuidaMInsabatoLZannoniGFet alDiagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer20202614172710.1007/s12253-020-00811-532377987Open DOISearch in Google Scholar
Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 immunohistochemistry in endometrial carcinomas. Int J Gynecol Pathol 2019; 38: S123-S131. doi: 10.1097/PGP.0000000000000488KöbelMRonnettBMSinghNSoslowRAGilksCBMcCluggageWGInterpretation of P53 immunohistochemistry in endometrial carcinomas201938S123S13110.1097/PGP.0000000000000488612700529517499Open DOISearch in Google Scholar
Ayhan A, Şahin H, Sari ME, Yalçin I, Haberal A, Meydanli MM. Prognostic significance of lymphovascular space invasion in low-risk endometrial cancer. Int J Gynecol Cancer 2019; 29: 505-12. doi: 10.1136/ijgc-2018-000069AyhanAŞahinHSariMEYalçinIHaberalAMeydanliMMPrognostic significance of lymphovascular space invasion in low-risk endometrial cancer2019295051210.1136/ijgc-2018-00006930665899Open DOISearch in Google Scholar
Oberndorfer F, Moling S, Hagelkruys LA, Grimm C, Polterauer S, Sturdza A, et al. Risk reclassification of patients with endometrial cancer based on tumor molecular profiling: First real world data. J Pers Med 2021; 11: 1-11. doi: 10.3390/jpm11010048OberndorferFMolingSHagelkruysLAGrimmCPolterauerSSturdzaAet alRisk reclassification of patients with endometrial cancer based on tumor molecular profiling: First real world data20211111110.3390/jpm11010048783051133467460Open DOISearch in Google Scholar
Colombo N, Creutzberg C, Amant F, Cibula D, Mirza MR, Marnitz S, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer. Int J Gynecol Cancer 2016; 26: 2-30. doi: 10.1097/igc.0000000000000609ColomboNCreutzbergCAmantFCibulaDMirzaMRMarnitzSet alESMO-ESGO-ESTRO consensus conference on endometrial cancer20162623010.1097/igc.0000000000000609467934426645990Open DOISearch in Google Scholar
Han G, Sidhu D, Duggan MA, Arseneau J, Cesari M, Clement PB, et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol 2013; 26: 1594-604. doi: 10.1038/modpathol.2013.102HanGSidhuDDugganMAArseneauJCesariMClementPBet alReproducibility of histological cell type in high-grade endometrial carcinoma201326159460410.1038/modpathol.2013.10223807777Open DOISearch in Google Scholar
Sobočan M, Ogrizek AM, Ledinek T, Takač I, Knez J. Importance of preoperative ultrasound examination and pathological tumour evaluation in the management of women with endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2021; 257: 121-126. doi: 10.1016/j.ejogrb.2020.12.029SobočanMOgrizekAMLedinekTTakačIKnezJImportance of preoperative ultrasound examination and pathological tumour evaluation in the management of women with endometrial cancer202125712112610.1016/j.ejogrb.2020.12.02933383411Open DOISearch in Google Scholar
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, et al. Uterine serous carcinoma. Gynecol Oncol 2021; 162: 226-34. doi: 10.1016/j.ygyno.2021.04.029BoganiGRay-CoquardIConcinNNgoiNYLMoricePEnomotoTet alUterine serous carcinoma20211622263410.1016/j.ygyno.2021.04.02933934848Open DOISearch in Google Scholar
Van Den Heerik ASVM, Horeweg N, De Boer SM, Bosse T, Creutzberg CL. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer 2021; 31: 594-604. doi: 10.1136/ijgc-2020-001822VanDen Heerik ASVMHorewegNDeBoer SMBosseTCreutzbergCLAdjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy20213159460410.1136/ijgc-2020-001822802008233082238Open DOISearch in Google Scholar
Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015; 113: 299-310. doi: 10.1038/bjc.2015.190TalhoukAMcConechyMKLeungSLi-ChangHHKwonJSMelnykNet alA clinically applicable molecular-based classification for endometrial cancers201511329931010.1038/bjc.2015.190450638126172027Open DOISearch in Google Scholar
Kommoss FKF, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, et al. L1cam further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer 2018; 119: 480-6. doi: 10.1038/s41416-018-0187-6KommossFKFKarnezisANKommossFTalhoukATaranFAStaeblerAet alL1cam further stratifies endometrial carcinoma patients with no specific molecular risk profile2018119480610.1038/s41416-018-0187-6613407630050154Open DOISearch in Google Scholar
Weinberger V, Bednarikova M, Hausnerova J, Ovesna P, Vinklerova P, Minar L, et al. A novel approach to preoperative risk stratification in endometrial cancer: The added value of immunohistochemical markers. Front Oncol 2019; 9: 1-13. doi: 10.3389/fonc.2019.00265WeinbergerVBednarikovaMHausnerovaJOvesnaPVinklerovaPMinarLet alA novel approach to preoperative risk stratification in endometrial cancer: The added value of immunohistochemical markers2019911310.3389/fonc.2019.00265647339431032226Open DOISearch in Google Scholar
Imboden S, Tapia C, Scheiwiller N, Kocbek V, Altermatt HJ, Janzen J et al. Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence. Acta Obstet Gynecol Scand 2020; 99: 196-203. doi: 10.1111/aogs.13740ImbodenSTapiaCScheiwillerNKocbekVAltermattHJJanzenJet alEarly-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence20209919620310.1111/aogs.1374031562818Open DOISearch in Google Scholar
Kolehmainen A, Pasanen A, Tuomi T, Koivisto-Korander R, Butzow R, Loukovaara M. Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. PLoS One 2020; 15:1-12. doi: 10.1371/journal.pone.0242733KolehmainenAPasanenATuomiTKoivisto-KoranderRButzowRLoukovaaraMClinical factors as prognostic variables among molecular subgroups of endometrial cancer20201511210.1371/journal.pone.0242733768542533232359Open DOISearch in Google Scholar
León-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, et al. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol 2020; 250: 312-22. doi: 10.1002/path.5373León-CastilloAGilvazquezENoutRSmitVTMcAlpineJNMcConechyMet alClinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas20202503122210.1002/path.5373706518431829447Open DOISearch in Google Scholar
Leon-Castillo A, De Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020; 38: 3388-97. doi: 10.1200/JCO.20.00549Leon-CastilloADe BoerSMPowellMEMileshkinLRMackayHJLearyAet alMolecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy20203833889710.1200/JCO.20.00549752715632749941Open DOISearch in Google Scholar